// startup autopsy
Sinovac Biotech
Chinese vaccine maker's US listing undone by governance battles and a going-private deal
founder chaosFire Sale
Distressed acquisition below last-round valuation · Fatal mistake: Chairman Weidong Yin's contested going-private offer created shareholder litigation and regulatory scrutiny that paralyzed operations of the US entity.
Key Events Timeline
FOUNDING
Sinovac Biotech established as a US-incorporated holding company for Chinese vaccine operations, pursuing NASDAQ listing.
PRODUCT LAUNCH
Launched hepatitis A vaccine Healive and expanded into influenza vaccines, gaining significant market share in China.
FUNDING
Completed final US capital raise of $9.6M as revenue growth slowed and competition in Chinese vaccine market intensified.
CEO CHANGE
Chairman Weidong Yin announced controversial going-private proposal, triggering shareholder opposition and legal disputes.
SHUTDOWN
Sinovac Biotech completed going-private transaction, delisting from US markets and ending its chapter as a US public company.